Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 122 resultados

PREMIER: Prioritisation and Risk Evaluation of Medicines in the EnviRonment GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2019-17-two-stage There are around 1900 active pharmaceutical ingredients (APIs) in use, yet the environmental risks of only a small proportion of these has b...
2020-06-24 - 2026-08-31 | Financiado

INNODIA HARVEST: Translational approaches to disease modifying therapy of type 1 diabetes HARVESTing the fruits of... GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2019-19-single-stage Building on the strong foundations of INNODIA, with its unique, Europe-wide clinical and basic research network for the study of type 1 diab...
2020-04-16 - 2024-04-30 | Financiado

ImmUniverse: Better control and treatment of immune mediated diseases by exploring the universe of microenvironme... GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enorm...
2019-12-17 - 2024-12-31 | Financiado

PharmaLedger: PharmaLedger GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage The PharmaLedger project will create a blockchain-based framework for the efficient digitization of the healthcare industry. The goal of the...
2019-12-16 - 2022-12-31 | Financiado

COMBINE: Collaboration for Prevention and Treatment of MDR Bacterial Infections GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage The loss of antibiotic effectiveness due to increasing antimicrobial resistance (AMR) is a serious threat to global public health. The IMI2...
2019-11-27 - 2025-10-31 | Financiado

3TR: Identification of the Molecular Mechanisms of non response to Treatments Relapses and Remission in... GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2018-14-two-stage 3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions...
2019-08-22 - 2026-08-31 | Financiado

UBIMOTIF: Short linear interaction motifs as specificity determinants in the ubiquitin system discovery mec... GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-MSCA-ITN-2019 A major challenge is the lack of therapeutic approaches for numerous human diseases, which poses a societal challenge. The ubiquitin system...
2019-08-09 - 2024-05-31 | Financiado

AB-DiRecT: Antibiotic Distribution and Recovery in Tissue GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2018-16-single-stage Antimicrobial resistance imposes an important health and economic burden with the threat of a future without effective antibiotics requiring...
2019-06-25 - 2023-09-30 | Financiado

MELLODDY: MachinE Learning Ledger Orchestration for Drug DiscoverY GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2018-14-two-stage MELLODDY will demonstrate how the pharmaceutical industry can better leverage its data assets to virtualize the Drug Discovery (DD) process...
2019-05-22 - 2022-05-31 | Financiado

ConcePTION: Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and... GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage ConcePTION partners have united around a shared vision that we have a societal obligation to radically and rapidly reduce uncertainty about...
2019-05-06 - 2024-12-31 | Financiado

IMMUcan: Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage IMMUcan proposes an inclusive and integrated European immuno-oncology platform. IMMUcan will access high-quality human biological material...
2019-04-23 - 2025-08-31 | Financiado

FAIRplus: FAIRplus GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage Wide sharing of knowledge and data drives the progression of science. Shared data allows other researchers to reproduce findings and benchma...
2018-12-18 - 2022-12-31 | Financiado

NECESSITY: NEw Clinical Endpoints in primary Sjögren s Syndrome an Interventional Trial based on stratifYing p... GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease (AID) involving 0.5 to 3/1000 persons. The disease affects exocrine glands...
2018-12-18 - 2025-12-31 | Financiado

MUSIQ: Multiphoton Microscopy and Ultrafast Spectroscopy Imaging meets Quantum GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-MSCA-ITN-2018 In the quest to decipher the chain of life from molecules to cells, the biophysical questions being asked increasingly demand techniques tha...
2018-08-30 - 2023-09-30 | Financiado

GetReal Initiative: The GetReal Initiative GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2017-11-single-stage The GetReal Initiative brings together partners from the IMI GetReal project to drive the adoption of tools, methodologies and best practice...
2018-06-26 - 2021-04-30 | Financiado

c4c: conect4children COllaborative Network for European Clinical Trials For Children GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage Paediatric medicines development is embedded in the European policy, legislation and in the work of the pharmaceutical industry but currentl...
2018-06-22 - 2025-04-30 | Financiado

EFOEUPATI: Ensuring the future of EUPATI beyond 2020 GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2017-11-single-stage The European Patients' Academy on Therapeutic Innovation (EUPATI) IMI project resulted in a number of key outputs for the field of patient e...
2018-06-21 - 2020-09-30 | Financiado

iConsensus: Integrated control and sensing platform for biopharmaceutical cultivation process high throughput de... GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage IConsensus will provide innovative analytical, hardware, software and high-throughput (HTP) solutions for the development, monitoring and co...
2018-06-21 - 2022-10-31 | Financiado

PARADIGM: Patients Active in Research and Dialogues for an Improved Generation of Medicines Advancing meaning... GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage PARADIGM will provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engage...
2018-06-04 - 2020-11-30 | Financiado

RTCure: Rheuma Tolerance for Cure GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. participó en un H2020: H2020-JTI-IMI2-2016-09-two-stage In line with IMI2 goals for improved therapies and precision medicine, the aim of this proposal is to prevent and treat RA or its progressio...
2017-08-25 - 2023-08-31 | Financiado

GSK